Factors shaping vaginal microbiota community long-term dynamics

Tsukushi Kamiya^{1,*}, Nicolas Tessandier¹, Baptiste Elie^{1,3}, Claire Bernat^{3,4}, Vanina Boué², Sophie Grasset², Soraya Groc^{2,3}, Massilva Rahmoun³, Christian Selinger^{2,5}, Michael S. Humphrys⁶, Marine Bonneau⁷, Christelle Graf⁷, Vincent Foulongne³, Jacques Reynes⁸, Vincent Tribout⁸, Michel Segondy³, Nathalie Boulle³, Jacques Ravel⁶, Carmen Lía Murall^{2,9}, and Samuel Alizon^{1,2,*} ¹Center for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS, INSERM, Université PSL, Paris, France ²MIVEGEC, CNRS, IRD, Université de Montpellier, France ³Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, Montpellier, France. ⁴PCCEI, Univ. Montpellier, Inserm, EFS, Montpellier, France ⁵Swiss Tropical and Public Health Institute, Basel, Switzerland ⁶Institute for Genomic Sciences, University of Baltimore, USA ⁷Department of Obstetrics and Gynaecology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France ⁸Department of Infectious and Tropical Diseases, Centre Hospitalier Universitaire de Montpellier, Montpellier, France ⁹National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Canada *Corresponding authors: tsukushi.kamiya@college-de-france.fr, samuel.alizon@college-de-france.fr

Abstract

The vaginal microbiota is structured into five main community state types (CST) that 2 are known to affect women's health. CST shifts can occur in less than a day, but there 3 is a lack of follow-ups lasting more than a few months; a gap in the knowledge that 4 hampers our understanding of long-term dynamics. Analysing a longitudinal cohort of 5 125 women followed for a median duration of 10 months, we show that 'optimal' (CST 6 I, II, and V) or 'sub-optimal' CST III are more stable in time than the 'non-optimal' 7 CST IV. We also find that some probabilities of shifting from one CST to another are 8 associated with covariates such reported number of sexual partners or alcohol consumption. g Finally, we simulate population-level consequences of variations in behaviours. In addition 10 to providing one of the first insights on vaginal microbiota dynamics over a year, along 11 with a robust methodological analysis, these results open new perspectives to improve 12 our mechanistic understanding of microbial interactions in the vaginal environment and 13 develop new therapeutic strategies. 14

Introduction

Epithelia of the human body are host to diverse arrays of microorganisms, referred to collectively as microbiota, that are tightly associated with our health. This is particularly true for the vaginal microbiota because its composition is strongly linked to the acquisition risk of many sexually transmitted infections (STIs) [1], fertility, especially in the context of medically-assisted procreation procedures [2], and general well-being [3].

Over the last two decades, meta-barcoding sequencing of 16S DNA revealed that the 21 variations in vaginal microbiota, which traces back to Albert Döderlein in 1892, can be 22 explained through five main community state types, or CSTs [4]. Three of these are 23 referred to as 'optimal' and are dominated by a lactobacillus species (L. crispatus for CST I, 24 L. gasseri for CST II, and L. jensenii for CST III). A fourth one, CST III, can be seen as 25 'sub-optimal' because it is dominated by L. iners, which is metabolically distinct from other 26 lactobacilli and can be associated with pathologies [5]. Finally, CST IV is characterised by 27 a diverse assemblage of other anaerobic bacterial species from the Gardnerella, Prevotella, 28 or Fannyhessea genera. This latter CST is the one usually associated with diseases such as 29 bacterial vaginosis [6]. Metagenomics and transcriptomics techniques have allowed us to 30 refine the compositional structure of these CSTs and to better understand their functioning 31 [7], yet a dynamical perspective is still starting to emerge. 32

The vaginal microbiota composition evolves through life [8] and daily variations have been scrutinised over a couple of months, with pioneering work analysing daily samples 34 during 16 weeks in 32 women [9]. While longer follow-ups exist, they either specifically 35 focus on pregnancy [10, 11], the samples are taken at large intervals (typically more than 36 three months) [12], or sample sizes are modest (< 100) [13]. These circumstances limit the 37 scope to generally understand the transient dynamics of vaginal microbiota in reproductive-38 aged women. Methodologically, many longitudinal studies aim to estimate the patterns of 39 transitions and stability among distinct community types [10, 11, 14]. However, the lack 40 of statistical power prevents these studies from examining how key risk factors modulate 41 community transitions. Therefore, despite the inherently dynamic nature of vaginal micro-42 biota communities, the current understanding of the impacts of key covariates — including 43 demography, lifestyle factors, sexual practices, or medication — relies almost entirely on 44 cross-sectional studies [15]. As such, there exists a knowledge gap in factors responsible 45 for stabilising and destabilising vaginal microbiota communities. 46

We explore vaginal microbiota long-term dynamics through a unique collection of 2,103 ⁴⁷ samples, which provide us with a high-resolution longitudinal follow-up of 125 women ⁴⁸ over more than 10 months for each on average. We implement Bayesian Markov models ⁴⁹ to estimate transition probabilities between CSTs, simultaneously estimating associations ⁵⁰ between the transitions and relevant covariates. Our study offers a new insight into the ⁵¹ stability and variability of the vaginal microbiota over a year and identifies important ⁵² covariates that can explain the variation we witness in human populations. ⁵³

Results

CSTs in the cohort

With 2,103 samples spanning over 1,323 total months of follow-up for 125 women, our 56 longitudinal dataset from the PAPCLEAR cohort represents one of the longest analysed 57 to date in the context of the vaginal microbiota (Figure 1). Study participants were be-58 tween 18 and 25 years old at inclusion and additional characteristics are shown in Table 1. 59 The majority of the samples (73.7%) were self-collected at home, the rest being collected 60 upon on-site clinical visits, and the most common interval between analysed samples were 61 seven and 14 days (Fig. 1a). The median follow-up duration was 8.64 (5.36, 14.0) months 62 (Fig. 1b). On average, each participant contributed 11 samples (Fig. 1c). 63

The metabarcoding analysis on 16S RNA allowed us to assign each sample to a CST ⁶⁴ (see the Methods). These were variable across women and over time (Fig. 1d). CST I, II, ⁶⁵ and V are considered 'optimal' but the latter two are rare, so we pooled all three in further ⁶⁶ investigation and refer to them as 'CST I(II, V)'. Overall, optimal communities were the ⁶⁷ most frequent, representing 44.5% of samples, followed by 'sub-optimal' (CST III) at 35.2% ⁶⁸ and 'non-optimal' communities (CST IV) at 20.4% (Fig. 1e). ⁶⁹

Probabilities of CST persistence

70

Given the longitudinal nature of our data, we used a continuous-time Markov model to 71 model CST variations over time (see the Methods). Simulations based on the estimated 72



Figure 1: Summary of vaginal microbiota samples analysed in the PAPCLEAR study. a) Intervals between sampling events for on-site clinical and home samples. b) Follow-up duration per participant. c) Number of samples analysed per participant d) Vaginal microbiota Community State Types (CST) over time in 125 participants. e) Frequency of the optimal (CST I, II, and V), sub-optimal (CST III) and non-optimal (CST IV) communities in all samples.

parameters of our model (i.e., a posterior predictive check), confirmed that it accurately captures the observed CST prevalence (Fig. 2a). The optimal, CST I(II, V), and suboptimal, CST III, communities showed a high degree of stability, with weekly probabilities to remain in the current state estimated at 87% (95% credibility interval, CrI, of 78 to 93%) and 81% (95% CrI of 68 to 90%), respectively. In contrast, the weekly persistence 77

Table 1: Summary profile of microbiota samples and covariates in the PAPCLEAR study. Q1 and Q3 refer to first (25%) and third (75%) quantiles. Level = 1 indicates the presence of a binary condition. See Appendix S1 for the covariate definitions.

	Level	Summary
Samples (Participants) CST (%) Sample type (%) Sampling interval (median (Q1,Q3)) Follow-up duration (median (Q1,Q3)) Samples per subject (median (Q1,Q3))	I(II,V) III IV Clinical Home	$\begin{array}{c} 2103 \ (125) \\ 935 \ (44.5) \\ 740 \ (35.2) \\ 428 \ (20.4) \\ 553 \ (26.3) \\ 1550 \ (73.7) \\ 21 \ (7, 28) \\ 8.64 \ (5.36, 14.0) \\ 11 \ (7, 16) \end{array}$
Covariates		
Identifying as 'Caucasian' $(\%)$	1	102 (81.6)
$BMI \pmod{(Q1,Q3)}$		21.19(19.78, 23.46)
Alcohol (median $(Q1,Q3)$)		3.14(1.40, 5.07)
Smoker (%)	1	36 (28.8)
Stress level (from 0 to 3, median $(Q1,Q3)$)		1.41 (1.00, 1.75)
Regular sport practice (%)	1	61 (48.8)
Red meat consumption (times per week, median $(Q1,Q3)$)		$0.50 \ (0.16, \ 1.00)$
Years since 1st menstructions (median $(Q1,Q3)$)		9(7, 10)
Hormonal contraception (%)	1	32(25.6)
Menstrual cup user (%)	1	46(36.8)
Vaginal product user (%)	1	73 (58.4)
Tampon user (%)	1	89 (71.2)
Lifetime number of partners (median $(Q1,Q3)$)		5(3, 11)
Lubricant use (%)	1	58(46.4)
Regular condom use by partner $(\%)$	1	23(18.4)
Male affinity $(\%)$	1	124 (99.2)
Chlamydia infection at inclusion (%)	1	7(5.6)
Pregnancy during follow-up (%)	1	4(3.2)
Vaginal douching $\binom{6}{2}$	1	4(3.2)
Spermicide user $(\%)$	1	1(0.8)
Female annity $(\%)$	1	10(8.0)
Systemic antibiotic treatment during the study $(\%)$	1	00(02.0)
Genital antibiotic treatment during the study $(\%)$	T	30(24.0)



Figure 2: Prevalence and transition probabilities among vaginal microbiota community state types (CSTs). a. Observed (bars) and predicted prevalence (crosses) of CSTs I (II, V), III and IV. The model predictions were generated by drawing 100 random samplings from the posterior distributions and simulating the Markov model for each sampled parameter set. b) Mean estimated weekly transition probabilities of CSTs I (II, V), III and IV. The arrow thickness indicates the persistence or transition probability.

probability of the non-optimal CST IV was only 60% (95% CrI of 32 to 80%, Fig. 2b). 78

79

Covariates effect on transitions

To gain a mechanistic understanding of the CST shifts, we estimate the effect of covariates ⁸⁰ jointly with the transition probabilities. Focusing on 16 covariates of interest and assuming ⁸¹ that they have a symmetrical effect on CST transitions, we identified alcohol consumption ⁸² as the most consistent driver of vaginal microbiota communities as it favoured the suboptimal over the optimal community (with 98% certitude, Fig. 3). This means that alcohol ⁸⁴



Figure 3: Estimated covariate effects on community transition rates. With the symmetry assumption, there are only three main types of transitions. The impact of covariates on community transition rates was estimated for a given set of community states as the log hazard ratio, β . The figure shows the posterior distributions of $\exp(\beta)$, the hazard ratio for the three sets of transition sets, and the corresponding 16 covariates. The numbers on the right-hand side of each panel indicate the probability that the estimated effect is different from the hazard ratio of 1 (i.e., the proportion of posterior distributions sampled on the dominant side of the effect).

consumption increases the pace of transition from CST I(II, V) to CST III or reduces that in the opposite direction by the same magnitude (our symmetry assumption does not allow us to distinguish between the two). In addition, alcohol consumption tended to favour CST IV over CST III (with 75% certitude, Fig. 3).

Other factors of possible effects on transitions (i.e., with more than 75% certitude) ⁸⁹ included self-reported Caucasian identity, number of sexual partners, use of vaginal intimate ⁹⁰ hygiene products, and body mass index (BMI). More precisely, identifying oneself as a ⁹¹ 'Caucasian' and having a larger BMI both appeared to favour CST III over CST I(II, V) ⁹² with 84 and 75% certitude, respectively. The number of sexual partners was also found to potentially favour CST IV over CST III, increasing the risk of maintaining (or transitioning to) CST IV with 88% certitude.

Finally, the use of vaginal hygiene products appeared to have multifaceted effects. ⁹⁶ Between CST I(II, V) and CST III, their use was positively linked to maintaining or ⁹⁷ transitioning to CST I(II, V) with 91% certitude. For the CST I(II, V) and CST IV pair, ⁹⁸ this product use tended to favour a shift towards CST IV, with an 84% certitude. Between ⁹⁹ CST III and CST IV, their use was more likely to support the persistence or move towards ¹⁰⁰ CST III, also with a 91% probability. These findings indicate that further mechanistic ¹⁰¹ understanding of individual products marketed for 'vaginal intimate hygiene' is warranted. ¹⁰²

103

Population-level consequence of covariate effects

Analysing transition rates at the individual level can help guide more mechanistic studies 104 at the within-host level, but they offer limited insights about population-level outcomes. 105 This is particularly true for covariates that are strongly involved in more than one type 106 of CST. Therefore, we performed simulations in which we varied a covariate while setting 107 all other factors to their representative reference value. Thanks to our estimated hazard 108 ratios (Fig. 3), we could predict the expected proportion of each CST in this simulated 109 population. This allowed us to see that covariates such as the reported use of vaginal 110 hygiene products, which are involved in many shits, appear to have a limited population 111 effect, with only a slightly decreasing frequency of CST IV with more frequent usage. 112



Figure 4: **Prevalence simulations predict population-level consequences of co-variates.** Based on estimated hazard ratios (Fig. 3), the population-level impact was simulated for each covariate. The vertical dashed lines indicate the intercept used in estimation: i.e., the population mean for continuous and 0.5 for binary variables. For continuous variables, the range of values explored was determined by the minimum and maximum values reported in the PAPCLEAR study.

Conversely, these simulations allowed us to confirm that the effect of alcohol on community transition rates translates into a marked decline in CST I prevalence in favour of CST 114 III at the population level in our simulations (Fig. 4). Compared to the average alcohol ¹¹⁵ consumer in this cohort, the predicted prevalence of the optimal community (CST I, II ¹¹⁶ and V) was 17% higher and lower for non-drinkers and the heaviest drinkers in the cohort, ¹¹⁷ respectively (>99% certitude). The alcohol-induced downfall of the optimal communities ¹¹⁸ is accompanied by an increase in both the sub- and non-optimal communities, although the ¹¹⁹ increasing trends are less certain separately. Nonetheless, the non-optimal CST IV tends ¹²⁰ to be 11% (>88% certitude) higher among average drinkers than non-drinkers. ¹²¹

Finally, as expected from the transition rates, population-level simulations predict that 122 an increasing number of sexual partners tends to reduce the prevalence of the sub-optimal 123 CST III with up to 92% certitude in favour of non-optimal CST IV (with up to 84% certi-124 tude). Perceived ethnic identity also hinted at trends at the population level as participants 125 who identified as 'Caucasian' were estimated to show an 11% higher occurrence of CST III 126 (with 84% certitude). We also find that CST IV (non-optimal) communities tend to be 127 less frequent in regular condom users (8% lower prevalence with 88% certitude), which is 128 consistent with previous association studies [16–18]. 129

Unobserved individual variability in community transition 130

While we incorporated 16 covariates into our model, some variations among women remain ¹³¹ unaccounted for. To quantify these, we estimated the extent of individual variability (i.e., ¹³² unobserved heterogeneity) in community transitions for each transition pair. ¹³³

The highest variability was observed among women in the transitions involving 'recov-



Figure 5: Individual-level variability in vaginal microbiota community state type transitions. a) The population average (thick black) and individual (thinner colours) weekly transition probabilities. b) Between-women individual variation for different transition combinations. Colours indicate the type of transition between CSTs.

ery' to an optimal CST from CST IV (Fig. 5). On the other hand, inverse transitions ¹³⁵ exhibited some of the lowest individual variability. The same is true, although to a lesser ¹³⁶ extent, for the shifts from sub-optimal CST III to optimal CSTs. ¹³⁷

These results suggest that there are limited pathways leading to the deterioration of ¹³⁸ vaginal microbiota communities, whereas the routes to recovery can be highly individualised. As these variations remained unexplained by the 16 covariates we investigated, ¹⁴⁰ further research attention is warranted to better understand the diversity of microbiota ¹⁴¹ recovery trajectory. ¹⁴²

Discussion

Vaginal microbiota is a key component of women's health. Pioneer work has studied its 144 daily variations for up to 16 weeks [9], but longer-term dynamics remain largely unknown. 145 By analysing follow-ups in 125 women with unprecedented length (more than 10 months) 146 on average and more than 16 samples per participant), we estimate the probabilities to 147 shift from one CST to another. These are consistent with the ones from earlier studies, 148 especially with a model that included the data from four cohorts [14]. Interestingly, in a 149 cohort following pregnant women, CST I was found to be more stable than in ours, which 150 could be due to hormonal changes [10]. 151

We also succeeded in testing the effect of relevant covariates on these transition rates, 152 while estimating them, which represents a strong methodological advance. We identify 153 several covariates with strong effects, some of which are echo earlier studies. For example, 154 the association between CST IV and the number of partners is consistent with the hypoth-155 esis that external importation of microbes could alter the dynamics of vaginal microbiota 156 and in line with earlier work []. The same is true for our result that (non-optimal) CST 157 IV tends to be less frequent in regular condom users, which is consistent with previous 158 association studies [16–18]. 159

Our study represents a rare European long-term cohort, yet it does not support a ¹⁶⁰ balanced design concerning ethnicity with over 80% of participants representing the Caucasian identity (Table 1). We do find that participants who do not identify themselves as ¹⁶² Caucasian are less found in CST I is consistent with many studies showing associations ¹⁶³ between self-perceived ethnicity and CST [4, 19, 20]. As the relative importance of biological, societal and environmental factors remains an open question [18], further studies are warranted to investigate in Europe. ¹⁶⁶

The reported use of products for vaginal hygiene (e.g. intimate soap) appears to have ¹⁶⁷ an effect on several transitions, which makes it difficult to link to a CST in particular. ¹⁶⁸ Finally, one of the strongest associations we find is between the amount of self-reported ¹⁶⁹ alcohol consumption and CST III. There are reports that go in this direction but, generally, ¹⁷⁰ there is little data on the link between diet and CST. ¹⁷¹

Strikingly, antibiotic consumption had little effect on CST transitions. This was true 172 for local treatment (genital application of metronidazole) or system treatment (antibiotic 173 treatment via oral intake). The strongest signal was between systemic use and CST III, 174 which is consistent with existing literature. An interpretation of this result is that CST 175 dynamics can be fast, as shown by daily monitoring. Therefore, since our sampling is 176 typically independent from treatment, CSTs are likely to have returned to a more basal 177 state when sampled. 178

These results have limitations. One of these is that, for our model to achieve convergence, we had to assume symmetry in the transition risks. This means that for alcohol consumption, for example, we do not know whether it increases the risk to shift away from an optimal CST or decreases the likelihood of leaving a sub-optimal CST. Another limitation inherent to all these studies is that even if we included many covariates, these patterns could be explained by 'hidden variables' or participants' general lifestyles.

184

Our model outputs, especially the inspection of the random effects, indicate that a 185 large part of the variability remains to be explained. One possibility could be that we miss 186 important covariates. Another could be that the CSTs classification level is too coarse. Fu-187 ture studies could analyse sub-CSTs, but this would greatly increase the number of possible 188 transitions, thereby raising an acute statistical challenge (here we already had to collapse 189 CSTs I, II, and V to introduce covariates into the model). In the same vein, analysing 190 metagenomics data could provide additional valuable insights on vaginal microbiota long-191 term dynamics [21]. For example, for women who appear to have stable CSTs, we could 192 identify the proportion of lineage replacements. This would also allow us to investigate the 193 effect of antibiotic treatments on the prevalence of resistance genes in the metagenome. 194

Finally, a promising avenue for future studies would be to jointly analyse CST dynamics 195 and sexually transmitted infections, especially human papillomaviruses (HPV). Earlier 196 studies have found a weak association between CST IV and the risk of HPV detection [22] 197 but the CST effect was tested after estimating transition rates and, more importantly, 198 this study pooled all high-risk HPV and all low-risk HPVs, making it difficult to identify 199 coinfections or reinfections. The PAPCLEAR cohort having genotype-specific follow-ups 200 [23], it could provide new insights into the link between CST and HPV infection, while 201 even identifying causal relationships. 202

Material and methods

Longitudinal clinical data

Samples originate from the PAPCLEAR monocentric longitudinal cohort study, which ²⁰⁵ followed N = 149 women longitudinally between 2016 and 2020. Its inclusion criteria were ²⁰⁶ to be between 18 and 25 years old, to live in the area of Montpellier, France, to be in good ²⁰⁷ health (no chronic disease), not to have a history of HPV infection (e.g., genital warts or ²⁰⁸ high-grade cervical lesion), and to report at least one new sexual partner over the last 12 ²⁰⁹ months. Additional details about the protocol can be found elsewhere [24]. ²¹⁰

Participants were enrolled by putting up posters and handing out leaflets at the main ²¹¹ sexually transmitted infection detection centre (CeGIDD) within the University Hospital ²¹² of Montpellier (CHU) and in the Universities of the city. To increase enrolment, posters ²¹³ were also hung at bus stops near the CHU. ²¹⁴

The inclusion visit was performed by a gynaecologist or a midwife at the CeGIDD ²¹⁵ outside operating hours. After an interview, several samples were collected, including ²¹⁶ vaginal swabs with eSwabs (Coppan) in Amies preservation medium. The samples were ²¹⁷ aliquoted right after the visit and stored at -20°C, before being transferred at -70°C within ²¹⁸ a month. Participants also filled in a detailed questionnaire, which formed the basis of ²¹⁹ epidemiological covariates analysed in this study. ²²⁰

Subsequent clinical visits were scheduled every 2 or 4 months, depending on the HPV 221 status. Between two visits, women were asked to perform 8 self-samples at home with 222

eSwabs in Amies medium and to keep them in their freezer. Samples were brought back 223 in an isotherm bag at the next visit. These were stored with the swab at -70°C until 224 processing. 225

Microbiota metabarcoding and quantification

The microbiota metabarcoding was performed on 200μ L of vaginal swabs specimen stored ²²⁷ at -70° in Amies medium. The DNA extraction was performed using the MagAttract ²²⁸ PowerMicrobiome DNA/RNA Kit (Qiagen). Next-generation sequencing of the V3-V4 ²²⁹ region of the 16S gene [25] was performed on an Illumina HiSeq 4000 platform (150 bp ²³⁰ paired-end mode) at the Genomic Resource Center at the University of Maryland School ²³¹ of Medicine. ²³²

The taxonomic assignment was performed using the internal software package SpeciateIT (https://github.com/Ravel-Laboratory/speciateIT) and the community state type was determined using the VALENCIA software package [26]. 235

Covariates

In the PAPCLEAR study, questionnaires were given to each participant to record patientlevel meta-data. In Supplementary Methods, we outline these variables with a variable label (in italics), brief description and relevance for the vaginal environment. 239

Out of the 22 covariates initially considered, we excluded six (*Chlamydia*, *Female* 240 affinity, *Male affinity*, *Pregnancy*, *Spermicide* and *Vag. douching*) as data were severely 241

skewed towards the most common value (> 90% of data). All these covariates are time-242 homogeneous meaning that the variation is among women, and static through time. To 243 facilitate the comparison of covariate effects, we centred and scaled continuous variables [27] 244 and deviation-coded binary variables. These transformations ensure that all covariates are 245 modelled in a comparable scale and the intercept is located at a "representative refer-246 ence value" of the modelled population. Four continuous covariates (i.e., Alcohol, BMI, 247 Partners, and Red meat) were log-transformed before scaling due to their right-skewed 248 distribution. 249

During their follow-ups, any use of medication was listed by the study staff. Within ²⁵⁰ these, we identified antibiotic treatments and separated the ones corresponding to 'Gynecological anti-infectives and antiseptics' ('G01' ATC codes), which all consisted in metronidazole treatments, to those corresponding to 'Antibacterials for systemic use' ('J01' ATC ²⁵³ codes), which were more diverse in terms of molecules. Since we had the exact dates of ²⁵⁴ treatment, these could be included as time-varying covariates into the model. ²⁵⁵

The model

Markov modelling

Markov models are statistical models used to represent systems that transition between ²⁵⁸ discrete states over time. These models are said to be 'memoryless', meaning that the ²⁵⁹ probability of transition to another state depends on the current state, but not its historical ²⁶⁰

256

path. In clinical research, these models are often used to predict the transitions among ²⁶¹ health states (e.g., health, illness and remission), and the propensity to transition between ²⁶² these states is estimated from longitudinal follow-up data. Because the exact timing of ²⁶³ these transitions is rarely known, clinical follow-up data are typically modelled using the ²⁶⁴ continuous-time Markov model [28], in which the probability of transition over a given ²⁶⁵ interval depends on the instantaneous transition intensity and the amount of time spent ²⁶⁶ in the current state. ²⁶⁷

Transition intensities

Transition intensities refer to the instantaneous rate of moving from state i to state j, a ²⁶⁹ process that may be affected by a vector of covariates, X. Taking the form of a proportional ²⁷⁰ hazards model, these rates can be expressed as: ²⁷¹

$$q_{p,i,j} = \operatorname{Exp}(\mu_{p,i,j} + \beta_{i,j} X), \tag{1}$$

where $\mu_{p,i,j}$ is the log-intercept, i.e. the baseline when all covariates are 0, and $\beta_{i,j}$ is 272 the log-coefficient expressing the impact of a covariate(s). This intercept is further defined 273 by the equation 274

$$\mu_{p,i,j} = (\hat{\mu}_{i,j} + s_{p,i,j}) \cdot \mu_{sd} + \bar{\mu},$$
(2)

where $\bar{\mu}$ and μ_{sd} are the prior mean and standard deviation of the log-intercept such 275 that $\hat{\mu}_{i,j} \cdot \mu_{sd} + \bar{\mu}$ constitutes the non-centred parameterisation of the population-level 276 intercept, $\mu_{i,j}$ and is assumed to be normally distributed, i.e., $\hat{\mu}_{i,j} \sim \mathcal{N}(0,1)$. 277

Additionally, we allow for unobserved heterogeneity in μ , i.e., $s_{p,i,j}$, where 278

$$\mathbf{s} = \operatorname{diag}(\mathbf{sd}_{\mathbf{s}}) \cdot \mathbf{L}_{\mathbf{s}} \cdot \mathbf{z}_{\mathbf{s}}.$$
(3)

We sample from the corresponding weakly informative priors, namely $sd_s \sim t_4(0,1)$, 279 $L_s \sim \text{LKJCorrCholesky}(2)$, and $z_s \sim \mathcal{N}(0,1)$, as recommended by the Stan development 280 community [29,30]. 281

For regression coefficients, the student-t distributions with degrees of freedom 4 to 7 are ²⁵² recommended as generic, weakly informative, priors [30]. We sampled β from $\beta \sim t_4(0,1)$, ²⁸³ which places a comparatively wide tail within the recommendation. As all of our covariates ²⁸⁴ have been proposed to impact vaginal microbiota communities *a priori* (see above), we did ²⁸⁵ not strongly regularise the priors, for example, through the use of the horseshoe priors [31]. ²⁸⁶ We note that all covariates were modelled simultaneously such that the interpretation of ²⁸⁷

each coefficient is conditional upon other covariates included and accounts for the influence 288 of other factors. We assumed that the covariates symmetrically affect the transitions (i.e., 289 $\beta_{j,i} = -\beta_{i,j}$), implying that the influence of any particular factor on moving from one 290 community state to another remains consistent, regardless of the direction the transition. 291

Collectively, the transition intensities form the Q matrix, in which the sum of intensities 292 across a row, i.e., all transitions from a particular state, is defined to be zero, such that we 293 have the following equation for the diagonal entries: 294

$$q_{i,i} = -\sum_{j \neq i} q_{i,j}.$$
(4)

Transition probabilities and likelihood

Taking the matrix exponential of the Q matrix for each participant, we compute the matrix 296 P such that: 297

$$P = \operatorname{Exp}((t_{k+1} - t_k) Q), \tag{5}$$

where k represents the sample identity for a given individual. The P matrix contains 298 the transition probabilities between two observations (at k and k+1) and $t_{k+1}-t_k$ indicates 299 the elapsed time between two observations. 300

Finally, the probability of observing a given state at the next sampling event (i.e. at $_{301}$ k+1) is modelled by the categorical distribution: $_{302}$

$$y_{k+1} \sim \text{Categorical}(P[y_k,])$$
 (6)

305

where $P[y_k]$ is the y_k th row of the P matrix containing the probabilities of transition 303 from the state observed at k.

Model fitting

We used a Bayesian approach to fit the above continuous-time Markov model to longitudinal data of vaginal microbiota CSTs. Our model was written in Stan 2.26.1 and fitted through the RStan interface 2.32.3 [32].

One participant lacked information on the years since their initial menstruation. We ³⁰⁹ imputed missing values using the mice package [33] and generated 20 imputed datasets ³¹⁰ to be fitted separately. For each imputed dataset, we fitted the model in parallel using ³¹¹ four independent chains, each with 2,000 sampled iterations and 1,000 warmup iterations. ³¹² The MCMC samples from separate runs (i.e., based on differently imputed data) were ³¹³ subsequently combined for inference. ³¹⁴

We confirmed over 4,000 combined effective samples and ensured convergence of independent chains ($\hat{R} < 1.1$) for all parameters [34]. We carried out a posterior predictive 316 check by comparing the observed and predicted CST frequency. We also quantified the $_{317}$ posterior z-score and posterior contraction to examine the accuracy and precision of pos- $_{318}$ terior distributions and the relative strength of data to prior information [35] (Supporting $_{319}$ Information S1).

Counterfactual predictions

We took advantage of the parameterised model to simulate the population-level outcomes ³²² of each covariate, assuming that all covariates, but a focal one, are at the representative ³²³ reference value (as described above) and then varying the focal parameter within the range ³²⁴ of values observed in the studied cohort. The model predictions were generated by ran-³²⁵ domly drawing 100 samplings from the posterior distributions and simulating the Markov ³²⁶ model for each sampled parameter set. We focused on the CST frequency as the outcome ³²⁷ of interest. ³²⁸

Acknowledgments

The authors thank Olivier Supplison for his helpful feedback. They acknowledge the ISO 330 9001 certified IRD i-Trop HPC (member of the South Green Platform) at IRD Montpellier 331 for providing HPC resources that have contributed to the research results reported within 332 this article (bioinfo.ird.fr and www.southgreen.fr). 333

DNA extracts were (partly) performed through the genotyping and sequencing facilities 334

of ISEM (Institut des Sciences de l'Evolution-Montpellier) and Labex Centre Méditerranéer	1 335
Environnement Biodiversité.	336

337

338

The raw data and R scripts used will be shared upon publication.

References

- van de Wijgert JHHM. The vaginal microbiome and sexually transmitted infections are interlinked: Consequences for treatment and prevention. PLoS Medicine. 340 2017;14(12):e1002478.
- Haahr T, Zacho J, Bräuner M, Shathmigha K, Skov Jensen J, Humaidan P. Reproductive outcome of patients undergoing in vitro fertilisation treatment and diagnosed with bacterial vaginosis or abnormal vaginal microbiota: a systematic PRISMA review and meta-analysis. BJOG. 2019;126(2):200–207.
- Bilardi JE, Walker S, Temple-Smith M, McNair R, Mooney-Somers J, Bellhouse C, ³⁴⁶
 et al. The Burden of Bacterial Vaginosis: Women's Experience of the Physical, Emo tional, Sexual and Social Impact of Living with Recurrent Bacterial Vaginosis. PLoS ³⁴⁸
 ONE. 2013;8(9):e74378.
- [4] Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SSK, McCulle SL, et al. Vaginal ³⁵⁰ microbiome of reproductive-age women. Proc Nat Acad Sci USA. 2011;108(S1):4680–³⁵¹ 4687.

- [5] France MT, Fu L, Rutt L, Yang H, Humphrys MS, Narina S, et al. Insight into the solve according to the solve analyses of metagenomic and meta-transcriptomic data. Genome Biology. 2022;23(1):66.
- [6] McKinnon LR, Achilles SL, Bradshaw CS, Burgener A, Crucitti T, Fredricks DN, ³⁵⁶ et al. The Evolving Facets of Bacterial Vaginosis: Implications for HIV Transmission. ³⁵⁷ AIDS Research and Human Retroviruses. 2019;35(3):219–228. ³⁵⁸
- [7] Holm JB, France MT, Gajer P, Ma B, Brotman RM, Shardell M, et al. Integrating 359
 compositional and functional content to describe vaginal microbiomes in health and 360
 disease. Microbiome. 2023;11(1):259.
- [8] Cancelo-Hidalgo MJ, Coello LB. Genitourinary Syndrome of the Menopause: Vaginal ³⁶²
 Health and Microbiota. In: Cano A, editor. Menopause: A Comprehensive Approach. ³⁶³
 Cham; 2017. p. 91–107. ³⁶⁴
- [9] Gajer P, Brotman RM, Bai G, Sakamoto J, Schutte UME, Zhong X, et al. Temporal Dynamics of the Human Vaginal Microbiota. Science Translational Medicine. 366 2012;4(132):132ra52–132ra52.
- [10] DiGiulio DB, Callahan BJ, McMurdie PJ, Costello EK, Lyell DJ, Robaczewska A, ³⁶⁸ et al. Temporal and spatial variation of the human microbiota during pregnancy. ³⁶⁹ Proceedings of the National Academy of Sciences. 2015;112(35):11060–11065. ³⁷⁰

- [11] Serrano MG, Parikh HI, Brooks JP, Edwards DJ, Arodz TJ, Edupuganti L, et al. 371
 Racioethnic diversity in the dynamics of the vaginal microbiome during pregnancy. 372
 Nature medicine. 2019;25(6):1001–1011. 373
- [12] Munoz A, Hayward MR, Bloom SM, Rocafort M, Ngcapu S, Mafunda NA, et al. 374
 Modeling the temporal dynamics of cervicovaginal microbiota identifies targets that 375
 may promote reproductive health. Microbiome. 2021;9(1):1–12. 376
- [13] Chaban B, Links MG, Jayaprakash TP, Wagner EC, Bourque DK, Lohn Z, et al. 377
 Characterization of the vaginal microbiota of healthy Canadian women through the 378
 menstrual cycle. Microbiome. 2014;2:1–12. 379
- Brooks JP, Buck GA, Chen G, Diao L, Edwards DJ, Fettweis JM, et al. Changes 380
 in vaginal community state types reflect major shifts in the microbiome. Microbial 381
 ecology in health and disease. 2017;28(1):1303265.
- [15] Ma B, Forney LJ, Ravel J. Vaginal Microbiome: Rethinking Health and Disease. 383
 Annual Review of Microbiology. 2012 Oct;66(1):371-389. Available from: http:// 384
 www.annualreviews.org/doi/10.1146/annurev-micro-092611-150157. 385
- [16] Hutchinson KB, Kip KE, Ness RB. Condom use and its association with bacterial vaginosis and bacterial vaginosis-associated vaginal microflora. Epidemiology. 2007;p. 387
 702–708. 388

- [17] Yotebieng M, Turner AN, Hoke TH, Van Damme K, Rasolofomanana JR, Behets F.
 Effect of consistent condom use on 6-month prevalence of bacterial vaginosis varies by
 baseline BV status. Tropical Medicine & International Health. 2009;14(4):480–486.
 391
- Borgdorff H, Veer Cvd, Houdt Rv, Alberts CJ, Vries HJd, Bruisten SM, et al. The 392
 association between ethnicity and vaginal microbiota composition in Amsterdam, the 393
 Netherlands. PLoS ONE. 2017;12(7):e0181135.
- [19] Zhou X, Brown CJ, Abdo Z, Davis CC, Hansmann MA, Joyce P, et al. Differences ³⁹⁵ in the composition of vaginal microbial communities found in healthy Caucasian and ³⁹⁶ black women. ISME J. 2007;1(2):121–133.
- [20] Fettweis JM, Brooks JP, Serrano MG, Sheth NU, Girerd PH, Edwards DJ, et al. Differences in vaginal microbiome in African American women versus women of European ancestry. Microbiology. 2014;160(Pt 10):2272.
- [21] France M, Ma B, Ravel J. Persistence and In Vivo Evolution of Vaginal Bacterial 401
 Strains over a Multiyear Time Period. mSystems. 2022 Nov;0(0):e00893-22. Publisher: 402
 American Society for Microbiology. Available from: https://journals.asm.org/ 403
 doi/10.1128/msystems.00893-22. 404
- [22] Brotman RM, Ravel J, Bavoil PM, Gravitt PE, Ghanem KG. Microbiome, sex hor ⁴⁰⁵ mones, and immune responses in the reproductive tract: Challenges for vaccine devel ⁴⁰⁶ opment against sexually transmitted infections. Vaccine. 2014;32(14):1543–1552.

- [23] Beneteau T, Groc S, Murall CL, Boué V, Elie B, Tessandier N, et al.. HPV detection 408 patterns in young women from the PAPCLEAR longitudinal study: implications for 409 HPV screening policies. medRxiv; 2023. Available from: https://www.medrxiv.org/ 410 content/10.1101/2023.09.30.23296382v1.
- Murall CL, Rahmoun M, Selinger C, Baldellou M, Bernat C, Bonneau M, et al. 412
 Natural history, dynamics, and ecology of human papillomaviruses in genital infections of young women: protocol of the PAPCLEAR cohort study. BMJ Open. 414
 2019;9(6):e025129. 415
- [25] Frank JA, Reich CI, Sharma S, Weisbaum JS, Wilson BA, Olsen GJ. Critical Evaluation of Two Primers Commonly Used for Amplification of Bacterial 16S rRNA Genes. 417
 Appl Environ Microbiol. 2008;74(8):2461. 418
- [26] France MT, Ma B, Gajer P, Brown S, Humphrys MS, Holm JB, et al. VALENCIA: 419
 a nearest centroid classification method for vaginal microbial communities based on 420
 composition. Microbiome. 2020;8(1):166. 421
- [27] Gelman A. Scaling regression inputs by dividing by two standard deviations. Statistics 422
 in medicine. 2008;27(15):2865–2873.
- [28] Christopher H Jackson. Multi-State Models for Panel Data: The msm Package for R.
 Journal of Statistical Software. 2011;38(8):1–29.

- [29] Stan Development Team. Stan Functions Reference; 2023. Accessed: 2024-02-24. 426
 Available from: https://mc-stan.org/docs/functions-reference/index.html. 427
- [30] Stan Development Team. Prior Choice Recommendations; 2023. Accessed: 2024-02- 428
 15. https://github.com/stan-dev/stan/wiki/Prior-Choice-Recommendations. 429
- [31] Piironen J, Vehtari A. Sparsity information and regularization in the horseshoe and 430 other shrinkage priors. Electronic Journal of Statistics. 2017;11(2):5018–5051.
- [32] Stan Development Team. RStan: the R interface to Stan; 2023. R package version 432
 2.32.3. Available from: https://mc-stan.org/.
- [33] van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained
 Equations in R. Journal of Statistical Software. 2011;45(3):1–67.
- [34] Stan Development Team. The Stan Core Library; 2018. Version 2.18.0. Available 436
 from: http://mc-stan.org/17.
- [35] Betancourt M. Towards a principled Bayesian workflow; 2020.
- [36] Farage M, Maibach H. Lifetime changes in the vulva and vagina. Archives of gynecology and obstetrics. 2006;273:195–202.
- [37] Loganantharaj N, Nichols WA, Bagby GJ, Volaufova J, Dufour J, Martin DH, et al.
 The effects of chronic binge alcohol on the genital microenvironment of simian im-

munodeficiency virus-infected female rhesus macaques. AIDS research and human 443 retroviruses. 2014;30(8):783–791. 444

- [38] Mayer BT, Srinivasan S, Fiedler TL, Marrazzo JM, Fredricks DN, Schiffer JT. Rapid
 and profound shifts in the vaginal microbiota following antibiotic treatment for bac terial vaginosis. The Journal of infectious diseases. 2015;212(5):793–802.
- [39] Si J, You HJ, Yu J, Sung J, Ko G. Prevotella as a hub for vaginal microbiota under the influence of host genetics and their association with obesity. Cell host & microbe. 2017;21(1):97–105.
- [40] Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. Vaginal 451
 microbiome of reproductive-age women. Proceedings of the National Academy of 452
 Sciences. 2011;108(supplement_1):4680-4687.
- [41] Brotman RM, He X, Gajer P, Fadrosh D, Sharma E, Mongodin EF, et al. Association
 between cigarette smoking and the vaginal microbiota: a pilot study. BMC infectious
 diseases. 2014;14(1):1–11.
- [42] Achilles SL, Austin MN, Meyn LA, Mhlanga F, Chirenje ZM, Hillier SL. Impact of 457
 contraceptive initiation on vaginal microbiota. American journal of obstetrics and 458
 gynecology. 2018;218(6):622–e1. 459
- [43] Laniewski P, Owen KA, Khnanisho M, Brotman RM, Herbst-Kralovetz MM. Clinical 460 and personal lubricants impact the growth of vaginal lactobacillus species and colo- 461

nization of vaginal epithelial cells: an in vitro study. Sexually transmitted diseases. 462 2021;48(1):63–70. 463

- [44] Tessandier N, Uysal IB, Elie B, Selinger C, Bernat C, Boué V, et al. Does exposure 464
 to different menstrual products affect the vaginal environment? Molecular Ecology. 465
 2023;32(10):2592–2601. 466
- [45] Vodstrcil LA, Twin J, Garland SM, Fairley CK, Hocking JS, Law MG, et al. The 467
 influence of sexual activity on the vaginal microbiota and Gardnerella vaginalis clade 468
 diversity in young women. PLOS One. 2017;12(2):e0171856. 469
- [46] Noormohammadi M, Eslamian G, Kazemi SN, Rashidkhani B. Association between 470
 dietary patterns and bacterial vaginosis: a case–control study. Scientific Reports. 471
 2022;12(1):12199. 472
- [47] Pape K, Ryttergaard L, Rotevatn TA, Nielsen BJ, Torp-Pedersen C, Overgaard C, 473
 et al. Leisure-time physical activity and the risk of suspected bacterial infections. 474
 Medicine and science in sports and exercise. 2016;48(9):1737–1744. 475
- [48] Amabebe E, Anumba DO. Psychosocial stress, cortisol levels, and maintenance of 476 vaginal health. Frontiers in endocrinology. 2018;p. 568.
- [49] Klebanoff MA, Nansel TR, Brotman RM, Zhang J, Yu KF, Schwebke JR, et al. 478
 Personal hygienic behaviors and bacterial vaginosis. Sexually transmitted diseases. 479
 2010;37(2):94.

- [50] Van Kessel K, Assefi N, Marrazzo J, Eckert L. Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: a systematic review.
 482 Obstetrical & gynecological survey. 2003;58(5):351–358.
- [51] Ma ZS. Microbiome transmission during sexual intercourse appears stochastic and 484
 supports the red queen hypothesis. Frontiers in Microbiology. 2022;12:789983.
- [52] Juliana NC, Peters RP, Al-Nasiry S, Budding AE, Morré SA, Ambrosino E. Composition of the vaginal microbiota during pregnancy in women living in sub-Saharan Africa:
 a PRISMA-compliant review. BMC pregnancy and childbirth. 2021;21(1):1–15.
- [53] Gupta K, Hillier SL, Hooton TM, Roberts PL, Stamm WE. Effects of contraceptive 489
 method on the vaginal microbial flora: a prospective evaluation. The Journal of 490
 infectious diseases. 2000;181(2):595–601.
- [54] Brotman RM, Klebanoff MA, Nansel TR, Andrews WW, Schwebke JR, Zhang J, 492
 et al. A longitudinal study of vaginal douching and bacterial vaginosis—a marginal 493
 structural modeling analysis. American journal of epidemiology. 2008;168(2):188–196. 494
- [55] Team SD. Stan Functions Reference; 2024. Accessed: 2024-02-05. https://mc-stan. 495 org/docs/functions-reference. 496

Supplementary methods

Competing interests

JReynes reports personal fees from Gilead (consulting and payment or honoraria for lec-499 tures, presentations, speaker's bureaus, manuscript writing, or educational events), Janssen 500 (payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, 501 or educational events), Merck (payment or honoraria for lectures, presentations, speaker's 502 bureaus, manuscript writing, or educational events), Theratechnologies (payment or hon-503 oraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational 504 events), and ViiV Healthcare (consulting and payment or honoraria for lectures, presen-505 tations, speaker's bureaus, manuscript writing, or educational events) and support for 506 attending meetings and/or travel from Gilead and Pfizer, outside of the submitted work. 507

JRavel is co-founder of LUCA Biologics, a biotechnology company focusing on translating microbiome research into live biotherapeutics drugs for women's health. He is Editorin-Chief at *Microbiome*.

All the other authors do not report any conflict of interest.

Ethics

The PAPCLEAR study was promoted by the CHU of Montpellier (France). This study ⁵¹³ has been approved by the Comité de Protection des Personnes (CPP) Sud Méditerranée ⁵¹⁴ I (reference number 2016-A00712-49); by the Comité Consultatif sur le Traitement de ⁵¹⁵

498

512

l'Information en matière de Recherche dans le domaine de la Santé (reference number 516 16.504); by the Commission Nationale Informatique et Libertés (reference number MMS/ 517 ABD/AR1612278, decision number DR-2016–488), by the Agence Nationale de Sécurité 518 du Médicament et des Produits de Santé (reference 20160072000007), and is registered at 519 ClinicalTrials.gov under the ID NCT02946346. 520

Funding

This project has received funding from the European Research Council (ERC) under the 522 European Union's Horizon 2020 research and innovation programme (grant agreement No 523 648963, to SA). The authors acknowledge further support from the Fondation pour la 524 Recherche Medicale (to TK), the Agence Nationale de la Recherche contre le SIDA (ANRS-525 MIE, to NT and OS), and the MemoLife Labex (to BE). 526

S1: Description of the study covariates

- 1st menstr. Number of years since the first menstruation: The morphology of the human vagina 528 changes throughout the life of a woman and the onset of puberty marks a key event 529 that triggers cascading changes [36]. 530
 - Alcohol Average number of glasses of alcoholic drinks consumed per week: Chronic presence 531 of alcohol in the genital environment has been linked to a shift in the immune and 532 microbiological conditions [37]. 533

527

- Antibiotics Consumption of antibiotics during the study: The bacterial composition responds ⁵³⁴ rapidly and transiently to antibiotics treatments that target bacteria either broadly ⁵³⁵ or with a narrow taxonomic scale [38]. ⁵³⁶
 - *BMI* Body mass index (BMI): Obesity has been implicated in elevating vaginal microbiota ⁵³⁷ diversity and promoting *Prevotella* associated with bacterial vaginosis [39]. ⁵³⁸
- Caucasian Identity as Caucasian ethnicity: Ethnicity has been linked to variation in vaginal microbiota compositions in several studies [40]. However, causal mechanisms remain an open question.
- Cigarettes Cigarette smoking: Smoking has been implicated in the development of BV due to its anti-estrogenic effects and the presence of harmful substances such as benzo[a]pyrene diol epoxide (BPDE). [41].
- Horm. contra. Use of hormonal contraception during the study: The vaginal hormonal landscape is 545 affected by the use of hormonal contractions [42]. 546
 - Lubricant Use of lubricant during the study: Personal lubricants contain various chemicals that differentially impact the growth of vaginal microbes in-vitro [43].
 - Menstr. cup Use of menstrual cup during the study: The vaginal microenvironmental may be altered by the use of menstrual cups both physically and chemically. An elevated risk of fungal infections has been reported [44].

- Partners Cumulative number of sexual partners: The genital microbiome can be transferred 552 between sexual partners [45]. Such an external input could destabilise the resident 553 community. 554
- Red meat Average number of meals that include red meat consumption per week: Diet alters the vaginal environment for microbes. An unhealthy diet, linked to a high proportion of red meat consumption, has been linked to an elevated risk of BV [46].
- Regular condom Regular use of condoms during sexual intercourse: Condom use can modify the vaginal microenvironment by altering the exchange of microbes between partners [16]. 559
 - Regular sport Engaging in regular sporting activities, over 50% of the time: Physical activities ⁵⁶⁰ influence immune responses, with leisure-time physical activity associated with a ⁵⁶¹ reduced risk of suspected bacterial infections compared to sedentary behaviour [47]. ⁵⁶²
 - Stress Average stress level reported from 0 (min) to 3 (max): Stress hormones may disrupt vaginal flora, for instance, by inhibiting glycogen production, which is the primary fuel for lactobacilli [48].
 - Tampon Use of tampons during the study: The use of internal contraceptives like tampons directly alters the vaginal environment, although negative effects from tampon use are seldom reported [49].
 - Vag. product Use of vaginal cream/tablet/capsule/gel/wipe during the study: Women frequently 569 use over-the-counter vulvovaginal treatments that contain a variety of chemical com-570

	ponents. However, the clinical effectiveness of these products in preventing bacterial	571
	vaginosis (BV) is seldom systematically evaluated [50].	572
Chlamydia	Tested positive for chlamydia	573
Female affinity	Affinity to female: Genital microbiome transfers during sexual activity are anticipated	574
	to vary based on the genders of the partners [51]	575
Male affinity	Affinity to male: Genital microbiome transfers during sexual activity are anticipated	576
	to vary based on the genders of the partners [51]	577
Pregnancy	History of pregnancy: Pregnancy significantly changes the cervicovaginal environ-	578
	ment, with increased estrogen from the ovaries and placenta leading to higher vaginal	579
	glycogen. This supports the growth of Lactobacillus species [52].	580
Spermicide	Use of spermicide during study: Spermicides use chemicals to prevent sperm from	581
	reaching an egg, but their use can change vaginal microflora, potentially increasing	582
	the risk of genitourinary infections [53].	583
Vag. douching	Use of vaginal douching during study: Vaginal douching, the practice of washing in-	584
	side the vagina with a liquid solution, has been shown to increase the risk of disturbing	585
	the natural balance of vaginal flora [54].	586

Supplementary Results

S2: Pairwise correlations between covariates

587

There were no strong correlations among covariates, with the strongest correlation found $_{589}$ between BMI and stress (r = 0.41). $_{590}$



Figure S1: Correlation between covariates. Pairwise Pearson's correlation coefficients between covariates

We leveraged the properties of posterior distributions to identify potential model fitting problems that might manifest from our model assumptions. To examine the accuracy and precision of posterior distributions, we first generated simulated observations based on the estimated posterior mean parameters. We then refitted our model to the simulated observations (i.e., secondary fitting) to compute the posterior z-score for each parameter, which measures how closely the posterior recovers the parameters of the data generating process [35]:

$$z = \frac{\mathbb{E}_{\rm sim} - \mathbb{E}_{\rm post}}{\sigma_{\rm sim}},$$

where \mathbb{E}_{post} denotes the posterior mean of the fit to the actual data that we consider the 'true' parameter. \mathbb{E}_{sim} and σ_{sim} denote the mean and standard deviation of the posterior distribution of the secondary fitting. The smaller the z-score, the closer the bulk of the posterior is to the true parameter [35]. In contrast, large z-values may be indicative of overfitting and, or poor prior specifications [35]. 596

To examine the influence of the likelihood function in relation to prior information, we computed the posterior contraction, k:

$$k = 1 - \frac{\sigma_{\text{post}}^2}{\sigma_{\text{prior}}^2}$$

where σ_{post}^2 and σ_{prior}^2 correspond to the variance of posterior and prior distributions, respectively. The *k* values close to zero indicate that data contain little information (i.e., rendering priors strongly informative). Conversely, values close to 1 indicate that data are much more informative than the prior [35].

We found that the most of our model parameters and hyperparameters — were esti-601 mated with accuracy and precision and identifiability, with the absolute posterior z-scores 602 below three (Fig. S1). A small number of individual variation in transition rates, sd_s 603 showed a tendency towards overfitting (the absolute posterior z-scores above three). Thus, 604 caution might be warranted when interpreting the extent of between-women variation in 605 CST transition rates, a small number of z-scores exceeding the absolute number of three 606 is unlikely to be a cause of concern [35]. We found that the posterior distributions for 607 covariate coefficients, β , contracted by over 75% compared to the prior distribution, for all 608 but one covariate effect, meaning that the covariate coefficients were well-identified from 609 data (Fig. S1). Although we used generic priors recommended by Stan [55], the L_s param-610 eters that define correlations among between-woman variation showed limited posterior 611 contraction (i.e., $\leq \sim 0.25$), indicating that these parameters are poorly informed by data. 612 As such, we refrain from making biological inferences about these correlations. 613



Figure S2: Accuracy, precision and identifiability of estimated parameters. Posterior z-score (y-axis) measures how closely the posterior recovers the parameters of the true data-generating process and posterior contraction (x-axis) evaluates the influence of the likelihood function over the prior, respectively. Smaller absolute posterior z-scores indicate that the posterior accurately recovers the parameters of the data-generating process: the absolute value beyond three to four may indicate substantial bias [35]. The posterior contraction values close to one indicate that data are much more informative than the prior. The estimated parameters are represented by a filled dot.

S4: Predicted difference in community state type (CST) prevalence at 614 various counterfactual scenarios. 615

Our counterfactual simulations predicted that alcohol consumption and the number of 616 partners are factors that impact the population-level outcome in terms of the prevalence 617 of different community state types. 618

The prevalence of the optimal community (CST I (II, V)) in a counterfactual population 619 comprising the heaviest drinkers was predicted to be 37% lower than that of non-drinkers 620 (with >99% certitude) (Fig. S??). The prevalence difference of the sub-optimal and non-621 optimal communities in the same comparisons was an increase of 22% (98% certitude) and 622 16% (84% certitude), respectively. Similar comparisons between the populations of heaviest 623 drinkers and average drinkers yielded a reduction of 20% in the optimal communities (>99%) 624 certitude) and the population of average drinkers versus non-drinkers predicted a 17% lower 625 prevalence of the optimal communities. 626



Figure S2: Difference in community state type (CST) prevalence at predicted various counterfactual scenarios. The differences were calculated from posterior samples simulated at 0 and 1 for binary variables and at the population maximum and minimum values recorded by the PAPCLEAR for continuous variables (left panel). Additional differences were computed between the population maximum and mean (middle panel) and the population mean and minimum for continuous variables (right panel).